The Global Market for ADME-Toxicology Testing is Projected to Reach US$11.9 Billion by 2020

Growing Need to Reduce Drug Development Costs Drives the Global ADME-Toxicology Testing Market, According to a New Report by Global Industry Analysts, Inc.

GIA announces the release of a comprehensive global report on ADME-Toxicology Testing.  The global market for ADME-Toxicology Testing is projected to reach US$11.9 billion by 2020, driven by increase in the number of drugs under development and the growing focus on reducing drug development costs.

ADME testing, also known as the pharmacokinetics of a drug refers to testing of absorption, distribution, metabolism, and excretion of a pharmaceutical compound inside an organism. When toxicity studies are clubbed together with ADME, it is known as ADME-Tox or ADMET or ADME/Tox. Increasing focus on lowering costs and time during drug development are driving the adoption of ADME-toxicology testing worldwide. The traditional drug development model uses toxicity and efficacy testing in in-vivo models, while ADME was used during compound selection. A key reason attributed to late stage drug failures is the inability of drug candidates to mimic in humans the safety profiles witnessed in animal models. Pharmaceutical companies are therefore focusing on incorporating toxicology testing in early drug development stages to reduce number of drug failures at later stages due to ADME-Toxicology issues.

Future growth in the market will be driven by advancements in ADME-Tox technology in terms of enhanced accuracy and predictability. The growing need for pharmaceutical companies to augment the drug discovery pipeline is expected to drive the development and demand for novel assays for predicting ADME/Tox properties. The ADME-Tox (ADMET) market has long been dominated by in vivo technologies. While in vivo technologies still account for a major share of demand, in vitro technologies are expected to gather momentum and spearhead growth in the global market over the next few years. The trend is driven by growing ethical concerns over the use of animals, and the resultant decrease in use of animals in clinical trials. Hepatocyte testing represents the most prominent segment in in-vitro testing, owing to its close resemblance to in-vivo testing. Apart from in vitro technologies, in silico technologies are also expected to witness substantial growth in the coming years.

As stated by the new market research report on ADME-Toxicology Testing, the United States represents the largest market worldwide. Asia-Pacific is forecast to emerge as the fastest growing market with a CAGR of 16% over the analysis period. Growth in the region is primarily driven by the ongoing shift of research work to low cost countries, increased government support, and rising collaborations between foreign pharmaceutical companies and local research laboratories.

Key players covered in the report include ACEA Biosciences, Inc., ADMEcell, Inc., Agilent Technologies, Inc., Beckman Coulter, Inc., BioreclamationIVT, LLC, Cerep SA, Cyprotex PLC, Dassault Systèmes, Galapagos NV, PerkinElmer Inc., Promega Corporation, and Takara Bio Europe AB, among others.  

The research report titled “ADME-Toxicology Testing: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of market, current trends, growth drivers, new product introductions, recent industry activity of major companies. The report provides market estimates and projections for all major geographic markets including the US, Canada, Japan, Europe (France, Germany, Italy, UK and Rest of Europe), Asia-Pacific and Rest of World. Product categories analyzed in the report include Toxicology (In-Vivo and In-Vitro) and ADME Testing.